Cell Therapy Target Discovery
Oncology (e.g., CAR-T)
DiscoveryActive
Key Facts
About Augmenta Bioworks
Augmenta Bioworks, founded in 2021 and based in San Francisco, is a private, pre-clinical stage biotech leveraging synthetic biology to decode the human immune system. The company's core technology, DeepGrid™, combines advanced automation, microfluidics, high-throughput sequencing, and computational analysis to pinpoint rare, protective immune cells from which novel therapeutics can be derived. Augmenta operates a platform-plus-partnership business model, collaborating with pharmaceutical and biotech companies to discover antibodies, cell therapies, and immune modulators, positioning itself at the intersection of biologics discovery and personalized immunology.
View full company profileTherapeutic Areas
Other Oncology (e.g., CAR-T) Drugs
| Drug | Company | Phase |
|---|---|---|
| In Vivo Viral Vector Collaboration | Lupagen | Preclinical |